

**Remarks**

Further and favorable reconsideration is respectfully requested in view of the foregoing amendments and following remarks.

Thus, claim 1 has been amended to incorporate that portion of claim 8 which requires that the electron transport layer comprises a pyridine derivative. As a result of this amendment, claims 7-9, 11, 13, 15, 17 and 19 have been cancelled, and claims 10, 12, 14, 16, 18 and 20 have been amended to depend from claim 1.

Claim 1, as well as claims 2-6, have been amended to make minor editorial changes to place these claims in more conventional form according to U.S. practice.

As required by the Examiner, the abstract has been rewritten to contain less than 150 words, rendering the objection to the abstract moot.

The patentability of the presently claimed invention after entry of the foregoing amendments, over the disclosures of the references relied upon the Examiner in rejecting the claims, will be apparent upon consideration of the following remarks.

Initially, it is apparent that the rejection of claims 1-7, 9, 11, 13, 15, 17 and 19 under 35 U.S.C. §102(e) as being anticipated by Cosimbescu et al. (US '717) has been rendered moot in view of the claim amendments. That is, as indicated above, the subject matter of claim 8 (directed to the pyridine derivative), which is not subject to this rejection, has been incorporated into claim 1, which is the only independent claim in the application.

The rejection of claims 8, 10, 12, 14, 16, 18 and 20 under 35 U.S.C. §103(a) as being unpatentable over Cosimbescu et al. in view of Thompson et al. (US '656) is respectfully traversed.

The Examiner, after acknowledging that Cosimbescu et al. do not disclose a phenanthroline in the electron transport layer, relies on the Thompson et al. disclosure of BCP, a phenanthroline derivative, to be useful as a hole blocking layer which confines excitons in the electroluminescent layer. The phenanthroline derivative is referred to in claim 8 of the present application, but it is the pyridine derivative from claim 8, in the electron transport layer, that has been incorporated into amended claim 1. For this reason, the rejection based on Cosimbescu et al. in view of Thompson et al. should also be withdrawn.


Therefore, in view of the foregoing amendments and remarks, it is submitted that each of the grounds of objection and rejection set forth by the Examiner has been overcome, and that the application is in condition for allowance. Such allowance is solicited.

Information Disclosure Statement

The Examiner's attention is also directed to the Third Information Disclosure Statement, as well as the Request for Examiner-Initialed SB/08 form submitted concurrently herewith.

Respectfully submitted,

Guofang WANG et al.

By   
Michael R. Davis  
Registration No. 25,134  
Attorney for Applicants

MRD/pth  
Washington, D.C. 20005-1503  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
January 20, 2010